ARTICLE | Clinical News
Phase III psoriasis data for Xanelim
June 21, 2001 7:00 AM UTC
Xoma (XOMA) and partner Genentech (DNA) presented the complete analysis of a previously reported Phase III study of Xanelim, which met its primary end point of >75% reduction in psoriasis activity and...